Skip to main content
. 2010 Jan 25;159(4):856–871. doi: 10.1111/j.1476-5381.2009.00581.x

Figure 6.

Figure 6

Oral administration of deoxyelephantopin (DET) suppresses orthotopic TS/A mammary tumour growth in female BALB/c mice. Experimental design and details are in Figure S1B. Tumour growth was measured once every 3 days (days 7–31) in the eight experimental groups in (A1) and (A2). At the end of the study, tumours were excised and processed for immunohistochemical staining for cell proliferation with proliferating cell nuclear antigen (PCNA) in (B), tumour blood vessel with CD31 in (C) and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay in (D). A representative image of each treatment group is shown. PCNA-positive cells (%) calculated by [(number of positive (red) cells/total number of cells counted) ×100]. Relative CD31-positive areas (%) calculated by [(areas of positive (red) CD31 in treatment group/areas of positive CD31 in tumour group) ×100]. TUNEL-positive cells in (D) calculated by number of positive (reddish brown) cells. Data are mean ± SEM of six independent tumour samples from each group of mice. Each treatment group significantly different from tumour control is marked (*P < 0.05).